Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss

Osteoporosis International

Volumn 25, Issue 3, 2014, Pages 1151-1161

  Lindtner, R A ^a   Tiaden, A N ^b   Genelin, K ^a   Ebner, H L ^a   Manzl, C ^a   Klawitter, M ^b   Sitte, I ^a   Von Rechenberg, B ^b   Blauth, M ^a   Richards, P J ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Aminobisphosphonate; Bone marrow stromal cell; Mineralization; Osteogenic differentiation; Osteopontin; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; OSTEOPONTIN; ZOLEDRONIC ACID;

AGED; BONE DENSITY; BONE DEVELOPMENT; CELL CULTURE; CELL DIFFERENTIATION; DRUG EFFECTS; ENZYMOLOGY; FEMALE; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CELL DIFFERENTIATION; CELLS, CULTURED; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; OSTEOPONTIN; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84894566450     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2494-3     Document Type: Article

References (51)

1. Zaidi M (2007) Skeletal remodeling in health and disease. Nat Med 13:791-801
2. Raggatt LJ, Partridge NC (2010) Cellular and molecular mechanisms of bone remodeling. J Biol Chem 285:25103-25108
3. Rodríguez JP, Garat S, Gajardo H, Pino AM, Seitz G (1999) Abnormal osteogenesis in osteoporotic patients is reflected by altered mesenchymal stem cells dynamics. J Cell Biochem 75:414-423
4. Rodríguez JP, Montecinos L, Rios S, Reyes P, Martinez J (2000) Mesenchymal stem cells from osteoporotic patients produce a type I collagen-deficient extracellular matrix favoring adipogenic differentiation. J Cell Biochem 79:557-565
5. Hess R, Pino AM, Ríos S, Fernández M, Rodríguez JP (2005) High affinity leptin receptors are present in human mesenchymal stem cells (MSCs) derived from control and osteoporotic donors. J Cell Biochem 94:50-57
6. Perrini S, Natalicchio A, Laviola L et al (2008) Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis. Endocrinology 149:1302-1313
7. Zhang ZM, Jiang LS, Jiang SD, Dai LY (2009) Osteogenic potential and responsiveness to leptin of mesenchymal stem cells between postmenopausal women with osteoarthritis and osteoporosis. J Orthop Res 27:1067-1073
8. Dalle Carbonare L, Valenti MT, Zanatta M, Donatelli L, Lo Cascio V (2009) Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis. Arthritis Rheum 60:3356-3365
9. Egermann M, Heil P, Tami A, Ito K, Janicki P, Von Rechenberg B, Hofstetter W, Richards PJ (2010) Influence of defective bone marrow osteogenesis on fracture repair in an experimental model of senile osteoporosis. J Orthop Res 28:798-804
10. Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC (1996) Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 97:1732-1740
11. Silva MJ, Brodt MD, Ko M, Abu-Amer Y (2005) Impaired Marrow osteogenesis is associated with reduced endocortical bone formation but does not impair periosteal bone formation in long bones of SAMP6 mice. J Bone Miner Res 20:419-427
12. Kuro-o M, Matsumura Y, Aizawa H et al (1997) Mutation of the mouse klotho gene leads to a syndrome resembling aging. Nature 390:45-51
13. Kawaguchi H, Manabe N, Miyaura C, Chikuda H, Nakamura K, Kuro-o M (1999) Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low- turnover osteopenia. J Clin Invest 104:229-237
14. Bonyadi M, Waldman SD, Liu D, Aubin JE, Grynpas MD, Stanford WL (2003) Mesenchymal progenitor self-renewal deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null mice. Proc Natl Acad Sci U S A 100:5840-5845
15. Choi Y, Wright AC, Johnson FB (2008) Defects in telomere maintenance molecules impair osteoblast differentiation and promote osteoporosis. Aging Cell 7:23-31
16. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276-1287
17. Li B, Ling Chau JF, Wang X, Leong WF (2011) Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. J Cell Biochem 112:1229-1242
18. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G (1998) Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22:455-461
19. von Knoch F, Jaquiery C, Kowalsky M et al (2005) Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26:6941-6949
20. Duque G, Rivas D (2007) Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 22:1603-1611
21. Ebert R, Zeck S, Krug R et al (2009) Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 44:858-864
22. Wang C-Z, Chen S-M, Chen C-H et al (2010) The effect of the local delivery of alendronate on human adipose-derived stem cell-based bone regeneration. Biomaterials 31:8674-8683
23. Benisch P, Schilling T, Klein-Hitpass L et al (2012) The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PLoS One 7:e45142
24. Wolfe M, Pochampally R, Swaney W, Reger RL (2008) Isolation and culture of bone marrow-derived human multipotent stromal cells (hMSCs). Methods Mol Biol 449:3-25
25. Tiaden AN, Breiden M, Mirsaidi A, Weber FA, Bahrenberg G, Glanz S, Cinelli P, Ehrmann M, Richards PJ (2012) Human serine protease HTRA1 positively regulates osteogenesis of human bone marrow-derived mesenchymal stem cells and mineralization of differentiating bone-forming cells through the modulation of extracellular matrix protein. Stem Cells 30:2271-2282
26. Boonen S, Laan RF, Barton IP, Watts NB (2005) Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 16:1291-1298
27. Eastell R, Walsh JS, Watts NB, Siris E (2011) Bisphosphonates for postmenopausal osteoporosis. Bone 49:82-88
28. Russell RGG (2011) Bisphosphonates: the first 40 years. Bone 49:2-19
29. Flanagan AM, Chambers TJ (1989) Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. Bone Miner 6:33-43
30. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487
31. Breuil V, Cosman F, Stein L, Horbert W, Nieves J, Shen V, Lindsay R, Dempster DW (1998) Human osteoclast formation and activity in vitro: effects of alendronate. J Bone Miner Res 13:1721-1729
32. Hughes DE, McDonald BR, Russell RGG, Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term culture of human bone marrow. J Clin Invest 83:1930-1935
33. Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49:34-41
34. Plotkin LI, Bivi N, Bellido T (2011) A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone 49:122-127
35. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363-1374
36. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60:6001-6007
37. Im G-I, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS (2004) Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25:4105-4115
38. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147
39. Seeman E, Delmas PD (2006) Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261
40. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199
41. Diab DL, Watts NB (2012) Bisphosphonates in the treatment of osteoporosis. Endocrinol Metab Clin North Am 41:487-506
42. Thompson RN, Phillips JR, McCauley SH, Elliott JR, Moran CG (2012) Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br 94:385-390
43. Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS (2010) Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 72:161-168
44. Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294
45. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224-231
46. Golub EE, Boesze-Battaglia K (2007) The role of alkaline phosphatase in mineralization. Curr Opin Orthop 18:444-448
47. Kellinsalmi M, Mönkkönen H, Mönkkönen J, Leskelä HV, Parikka V, Hämäläinen M, Lehenkari P (2005) In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol 97:382-391
48. Giuliani N, Girasole G, Pedrazzoni M, Passeri G, Gatti C, Passeri M (1995) Alendronate stimulates b-FGF production and mineralized nodule formation in human osteoblastic cells and osteoblastogenesis in human bone marrow cultures. J Bone Miner Res 10:S171
49. Boskey AL, Spevak L, Paschalis E, Doty SB, McKee MD (2002) Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 71:145-154
50. Harmey D, Johnson KA, Zelken J, Camacho NP, Hoylaerts MF, Noda M, Terkeltaub R, Millán JL (2006) Elevated skeletal osteopontin levels contribute to the hypophosphatasia phenotype in Akp2(-/-) mice. J Bone Miner Res 21:1377-1386
51. Addison WN, Azari F, Sørensen ES, Kaartinen MT, McKee MD (2007) Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem 282:15872-15883